Table 1.
References | Phase | Sample size | Mean age | HLA | Lymph node | DTH (mm2)-case | DTH (mm2)-control | CD8+ T-cell (%)-case | Recurrence (%) | Overall survival (%) | DFS (%) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Control | Case | Control | Case | Control | Pre | Post | Pre | Post | Pre | Post | Case | Control | Case | Control | Case | Control | ||||
GP2 | aMittendorf [12]/Tommy [10] | II | 89 | 91 | 49 | A2+ | A2+ | 51N+ | 60N+ | 4.1 | 15.3 | 3.9 | 8 | 0.8 | 1.5 | 5.12 | 2.35 | 92.13 | 95.6 | 82.9 | 80.4 |
Clifton [30] | I | 17 | 0 | 47 | A2+, A3+ | 13N+ | 28 | 68 | 46*106 | 144*106 | |||||||||||
Carmichael [11] | I | 18 | 0 | 47 | A2+ | 18N− | 0 | 27.5 | 0.4 | 1.1 | |||||||||||
GP2 Total | 3 trials | 124 | 91 | ||||||||||||||||||
E75 | Clifton [7] | II | 136 | 139 | 51 | A2+, A3+, A24+, A26+ | 81N+ | 88N+ | 1.6 | 7.9 | 2 | 2.1 | 0.025 | 0.09 | 8.82 | 14.4 | 89.8 | 83.8 | |||
Clifton [32] | II | 81 | 69 | 52 | A2+, A3+, A24+, A26+ | A2+, A3+, A24+, A26+ | 49N+ | 44N+ | |||||||||||||
Mittendorf [8] | III | 382 | 376 | 51.8 | A2+, A3+ | A2+, A3+ | 373N+ | 366N+ | 6.3 | 9.8 | 77.1 | 77.5 | |||||||||
Mittendorf [9] | I, II | 108 | 79 | 55 | A2+, A3+ | A2−, A3− | 53N+ | 44N+ | 1.2 | 13.7 | 0.4 | 1.7 | 10 | 20 | 89.7 | 80.2 | |||||
Mittendorf [33] | I, II | 106 | 76 | 55 | A2+, A3+ | A2−, A3− | 51N+ | 43N+ | 5.6 | 13.1 | 94.3 | 86.8 | |||||||||
Holmes [34] | I, II | 53 | 0 | 58 | A2+, A3+ | 27N+ | NA | 99.4 | 0.3 | 0.99 | |||||||||||
Patil [22] | I, II | 106 | 81 | 56 | A2+, A3+ | A2−, A3− | 46N+ | 53N+ | 3 | 14 | 3.2 | 3.5 | 8.3 | 14.8 | |||||||
Gates [35] | I | 24 | 22 | 63 | A2+ | A2− | 5 | 31.5 | 1.6 | 9.7 | 28.6 | 26.3 | 95.2 | 100 | |||||||
Benavides [36] | II | 85 | 66 | 54 | A2+, A3+ | A2−, | 49N+ | 42N+ | 4 | 14.84 | NA | 1.1 | 0.73 | 1.83 | 11.7 | 18.2 | 98.8 | 92.42 | |||
Peoples [20] | II | 101 | 85 | 57 | A2+, A3+ | A2−, A3− | 45N+ | 46N+ | 0.5 | 14 | 1.4 | 2.1 | 0.39 | 1.8 | 5.6 | 14.2 | 99 | 95.1 | 92.5 | 77 | |
Holmes [23] | II | 99 | 0 | A2+, A3+ | 48N+ | 2.7 | 21.5 | 0.416 | 1.78 | 10.1 | |||||||||||
Amin [27] | II | 101 | 85 | A2+, A3+ | A2−, A3− | 45N+ | 46N+ | 12.8 | 13.625 | NA | 2.64 | 0.42 | 1.79 | 8.3 | 14.8 | 99 | 93.8 | 88 | 58 | ||
Stojadinovic [37] | I | 16 | NA | 52 | A2+ | 16N+ | NA | 22.3 | NA | 3 | 0.36 | 0.65 | |||||||||
Dehqanzada [38] | I, II | 36 | 0 | 59.7 | A2+ | A2− | 12N+ | ||||||||||||||
Dehqanzada [39] | I, II | 32 | 0 | 57 | A2+ | 10N+ | |||||||||||||||
Hueman [40] | II | 7 | 17 | A2+ | A2− | 7N− | 17N− | 58.8 | 67.4 | ||||||||||||
Hueman [41] | I | 22 | 22 | A2+ | A2− | 22N− | 22N− | 0.75 | 1.2 | ||||||||||||
Mittendorf [42] | I | 44 | 0 | A2+ | A2− | 24N+ | 0.5 | 1.68 | |||||||||||||
Peoples [21] | I | 24 | 29 | A2+ | A2− | 24N+ | 29N+ | NA | 33 | NA | 7 | 0.56 | 1.66 | 8.3 | 20.7 | 100 | 93 | 85.7 | 59.8 | ||
Murray [43] | I | 13 | 0 | 48 | A2+ | 6N+ | NA | 7.83 | |||||||||||||
Knutson [44] | I | 4 | 10 | 48 | A2+ | A2+ | |||||||||||||||
E75 Total | 21 trials | 1580 | 1156 |
NA not available, DTH delayed hypersensitivity reaction, HLA human leukocyte antigen, DTH delayed-type hypersensitivity reaction, DFS disease-free survival rate, HLA-A2± A2± human leukocyte antigen A2 positive/negative, HLA-A3± A3± human leukocyte antigen A3 positive/negative , HLA-A24± A24± human leukocyte antigen A24 positive/negative, HLA-A26± A26± human leukocyte antigen A26 positive/negative
aTommy A(2020) and Mittendorf EA(2016) 17reported the same clinical trial